Pestell v. CytoDyn Inc.

CourtDistrict Court, D. Delaware
DecidedMarch 18, 2022
Docket1:19-cv-01563
StatusUnknown

This text of Pestell v. CytoDyn Inc. (Pestell v. CytoDyn Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pestell v. CytoDyn Inc., (D. Del. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

RICHARD G. PESTELL, M.D., PH.D. PLAINTIFF / COUNTERCLAIM DEFENDANT

v. Case No. 1:19-cv-01563

CYTODYN, INC. and CYTODYN OPERATIONS, INC. DEFENDANTS / COUNTERCLAIM PLAINTIFFS

MEMORANDUM OPINION AND ORDER Before the Court is the motion for summary judgment filed by Defendants CytoDyn, Inc. and CytoDyn Operations, Inc. (ECF No. 111). This matter has been briefed and is ready for consideration. (ECF Nos. 112, 113, 120, 126). I. Background A. Procedural Background On August 22, 2019, Plaintiff Richard G. Pestell, M.D., Ph.D. filed his complaint against CytoDyn, Inc., CytoDyn Operations, Inc., Scott Kelly and Nader Pourhassan. (ECF No. 1). On September 16, 2019, Defendants1 filed a motion to dismiss Plaintiff’s complaint. (ECF No. 11). On September 27, 2019, Plaintiff filed his first amended complaint. (ECF No. 15). On October 10, 2019, Defendants CytoDyn, Inc. and CytoDyn Operations, Inc. (“Company Defendants”) filed a motion dismiss the first amended complaint. (ECF No. 17). On October 11, 2019, Defendants Kelly and Pourhassan filed a motion to dismiss the first amended complaint. (ECF No. 18). On June 12, 2020, the Court granted in part and denied in part the motion to dismiss filed by the Company Defendants (Order, ECF No. 30). The Court ordered that count two, Plaintiff’s claim under the Pennsylvania Wage Payment and Collection Law2 (“PWPCL”), of the first amended complaint was dismissed. Id. Since this was the only count against Defendants Kelly and

1 The Company Defendants filed the motion to dismiss. However, Defendants Scott Kelly and Nader Pourhassan were added when they filed their joinder. (ECF No. 14). 2 43 P.S. § 260.1, et seq. Pourhassan, their motion to dismiss was found moot. (Oral Order, ECF No. 32). On June 26, 2020, the Company Defendants filed an answer to Plaintiff’s first amended complaint and asserted counterclaims against Plaintiff. (ECF No. 31). On July 10, 2020, Plaintiff filed his second amended complaint realleging his PWPCL claims against the Company Defendants and Defendants Kelly and Pourhassan. (ECF No. 35). On July 17, 2020, Plaintiff filed his answer to the Company Defendants’ counterclaims. (ECF No. 36). On July 22, 2020, Plaintiff sought leave to file a third amended complaint. (ECF No. 37). On July 24, 2020, the Company Defendants filed a motion to dismiss, and Defendants Kelly and Pourhassan filed a motion to dismiss. (ECF Nos. 38, 39). Subsequently, Plaintiff filed yet his third amended complaint on July 27, 2020. (ECF No. 41). On November 2, 2020, the Court granted the Company Defendants’ motion to dismiss Plaintiff’s PWPCL claims asserted in Plaintiff’s third amended complaint. (ECF No. 49). As a result, the PWPCL claims against Defendants Kelly and Pourhassan were dismissed with prejudice and their motion to dismiss (ECF No. 39) was moot. (ECF No. 49). Plaintiff’s remaining claims are against the Company Defendants for breach of contract and defamation, and Plaintiff seeks an entry of declaratory judgment against the Company Defendants. Id. On November 16, 2020, the Company Defendants filed an answer and amended counterclaims to Plaintiff’s third amended complaint. (ECF No. 50). The Company Defendants counterclaims are for breach of contract for disclosure of confidential information, failure to return confidential information, and failure to return affirmation of compliance with covenants agreement under the parties’ employment agreement and covenants agreement. Id. The Company defendants also allege that Plaintiff breached a bill of sale, and they seek an entry of declaratory judgment against the Plaintiff. On November 24, 2020, Plaintiff filed his answer to the Company Defendants’ counterclaims. (ECF No. 52). On January 14, 2022, the Company Defendants filed a partial motion for summary judgment regarding Plaintiff’s claims for monetary damages under the “Madison Fund Rule” arising out of his inability to sell the Company Defendants’ Restricted Shares, regarding Plaintiff’s defamation claim, and regarding Defendants’ Counterclaims for breach of the employment agreement and the covenants agreement. (ECF No. 111). B. Factual Background Plaintiff joined the Company Defendants as their Chief Medical Officer (“CMO”) and as a Board member when the Company Defendants purchased ProstaGene, LLC (“ProstaGene”)—a privately held biotechnology start-up founded by Plaintiff—in an all-stock transaction which closed in November 2018. Upon Closing of the ProstaGene Transaction, the parties executed an employment agreement and Plaintiff became the Company Defendants’ CMO on a permanent basis. (ECF No. 113-5). Plaintiff was also appointed to the Company Defendants’ Board, as of the Closing date, and was later elevated to Vice- Chairman. Id. Section 4.1 of the employment agreement permitted the Company Defendants to terminate Plaintiff “for Cause” and Plaintiff to resign for “Good Reason.” (ECF No. 113-2). In the following months, disagreements began to arise between Plaintiff and the CEO, Nader Pourhassan. In June 2019, Pourhassan began to plan for the termination of Plaintiff. On July 22, 2019, Plaintiff sent a letter to Defendants in accordance with Section 4.1 of the employment agreement, which notified the Company as to conduct and conditions constituting “Good Reason” for Plaintiff to resign as an employee of the company and provided the Company Defendants the opportunity to cure these conditions. (ECF No. 120-3 at 8). On July 25, 2019, the Board of Directors made the decision to terminate Plaintiff. (ECF No. 113-1). On July 26, 2019, Defendants issued a press release stating that the Board had “terminated the employment of [Plaintiff] for cause pursuant to the terms of his employment agreement with the Company.” (Id. at 42–43). The same day, the Company Defendants filed a Form 8-K with the Securities and Exchange Commission (the “SEC”) stating that Plaintiff had been “terminated . . . for cause pursuant to the terms of his employment agreement.” (Id. at 48). The Company Defendants’ Schedule 14A Proxy Statement filed with the SEC on August 21, 2019 again represented that Plaintiff’s termination had been “for cause.” (Id. at 69); (id. at 84) (August 22, 2019 Form 8-K stating the same and disclosing Plaintiff’s filing of this lawsuit). On September 13, 2019, following Plaintiff’s termination, the Company Defendants sent Plaintiff a letter purporting to exercise the Repurchase Option pursuant to Sections 1(a) and 2 of the Stock Restriction Agreement. (Id. at 118–19). In the letter, the Company Defendants stated that it “expects to deliver to its Transfer Agent a letter which instructs the Transfer Agent to effect the transfer of the Restricted Stock to the Company’s name on or about September 18, 2019.” Id. On September 18, 2019, in response to the Exercise of Repurchase Option Notice Letter and the Company Defendants’ efforts to transfer the stock, Plaintiff notified Computershare Trust Company, N.A., the transfer agent, of the dispute as to the Company Defendants’ right to the stock and demanded that the stock remain in Plaintiff’s name pending resolution of this lawsuit. (Id. at 122–23). For approximately twenty months, Plaintiff remained the owner of record of the stock and continued to exercise his rights as the owner of the stock, including by continuing to vote his shares as he did previously. (ECF No. 87 at ¶ D). On May 27, 2021, the 8,342,000 shares were transferred out of Plaintiff’s Computershare account. (ECF No. 120-3 at 125). Ultimately, the Company Defendants stipulated to the return of the 8,342,000 shares to Plaintiff to be held in escrow. (ECF No. 87). Plaintiff has maintained his ownership interest in the 8,342,000 shares, but Plaintiff has been restricted from selling the stock. II. Standard of Review Under Fed. R. Civ. P.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Christianson v. Colt Industries Operating Corp.
486 U.S. 800 (Supreme Court, 1988)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
Haft v. Dart Group Corp.
877 F. Supp. 896 (D. Delaware, 1995)
Madison Fund, Inc. v. Charter Co.
427 F. Supp. 597 (S.D. New York, 1977)
Barker v. Huang
610 A.2d 1341 (Supreme Court of Delaware, 1992)
Gannett Co., Inc. v. Re
496 A.2d 553 (Supreme Court of Delaware, 1985)
Riley v. Moyed
529 A.2d 248 (Supreme Court of Delaware, 1987)
Ramunno v. Cawley
705 A.2d 1029 (Supreme Court of Delaware, 1998)
Agar v. Judy
151 A.3d 456 (Court of Chancery of Delaware, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Pestell v. CytoDyn Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/pestell-v-cytodyn-inc-ded-2022.